• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Vaccination saves lives: a real-time study of patients with chronic diseases and severe COVID-19 infection.接种疫苗挽救生命:慢性病和重症 COVID-19 感染患者的实时研究。
QJM. 2023 Feb 14;116(1):47-56. doi: 10.1093/qjmed/hcac202.
2
Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.斋浦尔市522例COVID-19住院患者的羟氯喹特性、治疗结果及作用:一项流行病学临床研究
J Assoc Physicians India. 2020 Jun;68(6):13-19.
3
Evaluation of a Hospitalized Pediatric COVID-19 Cohort from Indian National Clinical Registry of COVID-19.评估来自印度国家 COVID-19 临床登记处的住院儿科 COVID-19 队列。
Indian J Pediatr. 2023 Oct;90(10):1000-1007. doi: 10.1007/s12098-022-04449-w. Epub 2023 Feb 16.
4
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体(RES-Q-HR):一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
5
Clinical profile of hospitalized COVID-19 patients in first & second wave of the pandemic: Insights from an Indian registry based observational study.COVID-19 住院患者在第一波和第二波大流行期间的临床特征:来自印度基于观察性研究登记的观察结果。
Indian J Med Res. 2021 May;153(5&6):619-628. doi: 10.4103/ijmr.ijmr_1628_21.
6
Clinical and Epidemiological Features of SARS-CoV-2 Patients in SARI Ward of a Tertiary Care Centre in New Delhi.新德里一家三级医疗中心SARI病房中新冠病毒患者的临床和流行病学特征
J Assoc Physicians India. 2020 Jul;68(7):19-26.
7
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
8
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.印度基于灭活病毒的 SARS-CoV-2 疫苗 BBV152 的有效性:一项病例对照研究。
Lancet Infect Dis. 2022 Mar;22(3):349-356. doi: 10.1016/S1473-3099(21)00674-5. Epub 2021 Nov 23.
9
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
10
Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance.接种 COVID-19 疫苗与接种后时间和德尔塔变异株流行对有症状 SARS-CoV-2 感染的关联。
JAMA. 2022 Mar 15;327(11):1032-1041. doi: 10.1001/jama.2022.2068.

引用本文的文献

1
Post COVID sequelae among COVID-19 survivors: insights from the Indian National Clinical Registry for COVID-19.新冠病毒幸存者的新冠后后遗症:来自印度国家新冠病毒临床登记处的见解。
BMJ Glob Health. 2023 Oct;8(10). doi: 10.1136/bmjgh-2023-012245.
2
Determinants of post discharge mortality among hospitalized COVID-19 patients.住院 COVID-19 患者出院后死亡率的决定因素。
Indian J Med Res. 2023 Aug;158(2):136-144. doi: 10.4103/ijmr.ijmr_973_23.

接种疫苗挽救生命:慢性病和重症 COVID-19 感染患者的实时研究。

Vaccination saves lives: a real-time study of patients with chronic diseases and severe COVID-19 infection.

机构信息

From the Indian Council of Medical Research, New Delhi, India.

Postgraduate Institute of Medical Education & Research, Chandigarh, India.

出版信息

QJM. 2023 Feb 14;116(1):47-56. doi: 10.1093/qjmed/hcac202.

DOI:10.1093/qjmed/hcac202
PMID:36053197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9494346/
Abstract

OBJECTIVES

This study aims to describe the demographic and clinical profile and ascertain the determinants of outcome among hospitalized coronavirus disease 2019 (COVID-19) adult patients enrolled in the National Clinical Registry for COVID-19 (NCRC).

METHODS

NCRC is an on-going data collection platform operational in 42 hospitals across India. Data of hospitalized COVID-19 patients enrolled in NCRC between 1st September 2020 to 26th October 2021 were examined.

RESULTS

Analysis of 29 509 hospitalized, adult COVID-19 patients [mean (SD) age: 51.1 (16.2) year; male: 18 752 (63.6%)] showed that 15 678 (53.1%) had at least one comorbidity. Among 25 715 (87.1%) symptomatic patients, fever was the commonest symptom (72.3%) followed by shortness of breath (48.9%) and dry cough (45.5%). In-hospital mortality was 14.5% (n = 3957). Adjusted odds of dying were significantly higher in age group ≥60 years, males, with diabetes, chronic kidney diseases, chronic liver disease, malignancy and tuberculosis, presenting with dyspnoea and neurological symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95% CI: 4.6-7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4-0.7)] or two doses of anti-SARS CoV-2 vaccine [OR: 0.4 (95% CI: 0.3-0.7)] were protected from in-hospital mortality.

CONCLUSIONS

WHO ordinal scale at admission is the most important independent predictor for in-hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protection against mortality.

摘要

目的

本研究旨在描述住院的 2019 冠状病毒病(COVID-19)成年患者的人口统计学和临床特征,并确定纳入国家 COVID-19 临床登记处(NCRC)的住院 COVID-19 患者的结局决定因素。

方法

NCRC 是一个在印度 42 家医院运行的正在进行的数据收集平台。分析了 2020 年 9 月 1 日至 2021 年 10 月 26 日期间纳入 NCRC 的住院 COVID-19 患者的数据。

结果

对 29509 名住院成年 COVID-19 患者(平均年龄[标准差]:51.1[16.2]岁;男性:18752[63.6%])的分析显示,15678 名(53.1%)患者至少有一种合并症。在 25715 名(87.1%)有症状的患者中,发热是最常见的症状(72.3%),其次是呼吸急促(48.9%)和干咳(45.5%)。住院死亡率为 14.5%(n=3957)。年龄≥60 岁、男性、患有糖尿病、慢性肾脏病、慢性肝病、恶性肿瘤和结核病、出现呼吸困难和神经症状的患者,死亡的调整后比值比显著更高。入院时的世界卫生组织等级量表 4 或以上的患者死亡风险最高[5.6(95%置信区间:4.6-7.0)]。接受一剂[比值比:0.5(95%置信区间:0.4-0.7)]或两剂抗 SARS-CoV-2 疫苗的患者[比值比:0.4(95%置信区间:0.3-0.7)]可降低住院死亡率。

结论

入院时的世界卫生组织等级量表是 COVID-19 患者住院死亡的最重要独立预测因素。抗 SARS-CoV2 疫苗可显著降低死亡率。